Table 2 Uni- and multivariate Cox proportional-hazard analyses for disease progression in HCC patients

 Age

0.99 (0.98–1.00)

0.15

–

–

–

 Gender (m/f)

0.87 (0.58–1.29)

0.48

–

–

–

 Tumor grade (G1 vs. G2)

0.54 (0.30–0.97)

0.04*

0.54 (0.28–1.07)

0.08(*)

0.14

 Tumor grade (G3/G4 vs. G2)

1.14 (0.73–1.80)

0.56

1.25 (0.78–2.02)

0.35

 Tumor stage (stage II vs. stage I)

1.78 (1.06–3.00)

0.03*

1.73 (1.01–2.93)

0.04*

0.02

 Tumor stage (stage III/IV vs. stage I)

1.96 (1.19–3.24)

0.01*

2.12 (1.26–3.55)

< 0.01*

 IFNL3 rs4803217 genotype (CA/AA vs. CC)

1.10 (0.74–1.63)

0.65

–

–

–

 Age

1.03 (1.01–1.05)

0.02*

1.02 (1.00–1.04)

0.02*

0.93

 Gender (m/f)

1.10 (0.70–1.73)

0.67

–

–

–

 Tumor grade (G1 vs. G2)

0.50 (0.25–1.00)

0.05*

0.53 (0.27–1.07)

0.08(*)

0.25

 Tumor grade (G3/G4 vs. G2)

0.91 (0.53–1.55)

0.72

1.01 (0.58–1.75)

0.96

 Tumor stage (stage II vs. stage I)

0.94 (0.50–1.79)

0.85

–

–

-

-

 Tumor stage (stage III/IV vs. stage I)

1.31 (0.75–2.26)

0.34

–

–

 IFNL3 rs4803217 genotype (CA/AA vs. CC)

1.11 (0.71–0.74)

0.66

–

–

–